Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aptevo Therapeutics Inc.APVO · Entity 8337 | SVP, CMO | August 06, 2026 | August 11, 2026 |
| Mersana Therapeutics, Inc.MRSN · Entity 69982 | Chief Medical Officer | January 15, 2020 | January 16, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aptevo Therapeutics Inc.
Report date August 06, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 482 |
Ending reported balance
After 2026-08-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-06 · Exercise / conversion · Acquired 638 · Balance 638 F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Row 2 · 2026-08-06 · Tax withholding · Disposed 156 · Balance 482 F2: Represents shares withheld by Issuer to satisfy tax withholding obligations on the vesting of RSUs. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-06 · Exercise / conversion · Disposed 638 · Balance 0 F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F3: On August 6, 2025, the reporting person was granted 11,500 (638 post-split) RSUs, vesting on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
F2: Represents shares withheld by Issuer to satisfy tax withholding obligations on the vesting of RSUs.
F3: On August 6, 2025, the reporting person was granted 11,500 (638 post-split) RSUs, vesting on the first anniversary of the date of grant.
Mersana Therapeutics, Inc.
Report date January 15, 2020 · Filed January 16, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.16 · Expires 2030-01-15 | Direct | 82,500 |
Reported balance
After 2020-01-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-15 · Grant · Acquired 82,500 · Balance 82,500 F1: The options vest in equal quarterly installments over the first four years after the vesting commencement date, January 15, 2020. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 18,333 |
Reported balance
After 2020-01-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-01-15 · Grant · Acquired 18,333 · Balance 18,333 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon vesting. F3: The restricted stock units vest in equal annual installments over the first four years after the vesting commencement date, January 15, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest in equal quarterly installments over the first four years after the vesting commencement date, January 15, 2020.
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon vesting.
F3: The restricted stock units vest in equal annual installments over the first four years after the vesting commencement date, January 15, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2026 Filed Aug 11, 2026 01:35 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 638 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-343073 · ownership.xml · derivative · entry 3 Huebner Dirk · CIK 0001760345 · SVP, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 638 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F3 · derivative.exercise_date: On August 6, 2025, the reporting person was granted 11,500 (638 post-split) RSUs, vesting on the first anniversary of the date of grant. F3 · derivative.expiration_date: On August 6, 2025, the reporting person was granted 11,500 (638 post-split) RSUs, vesting on the first anniversary of the date of grant. Read SEC document |
| August 06, 2026 Filed Aug 11, 2026 01:35 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Tax withholdingCommon Stock | 156 | $4.07 | $634.92 |
DisclosureSEC source: 0001193125-26-343073 · ownership.xml · nonDerivative · entry 2 Huebner Dirk · CIK 0001760345 · SVP, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 482 F2 · kind: Represents shares withheld by Issuer to satisfy tax withholding obligations on the vesting of RSUs. Read SEC document |
| August 06, 2026 Filed Aug 11, 2026 01:35 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 638 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-343073 · ownership.xml · nonDerivative · entry 1 Huebner Dirk · CIK 0001760345 · SVP, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 20:34 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantRestricted Stock Unit · Derivative | 11,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-105935 · ownership.xml · derivative · entry 1 Huebner Dirk · CIK 0001760345 · SVP, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires not disclosed F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: The RSUs vest in full on the first anniversary of the date of grant. F2 · derivative.expiration_date: The RSUs vest in full on the first anniversary of the date of grant. Read SEC document |
| January 15, 2020 Filed Jan 16, 2020 21:34 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantRestricted Stock Units · Derivative | 18,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-004774 · a4.xml · derivative · entry 2 Huebner Dirk · CIK 0001760345 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,333 Underlying: Common Stock · 18,333 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: The restricted stock units vest in equal annual installments over the first four years after the vesting commencement date, January 15, 2020. F3 · derivative.expiration_date: The restricted stock units vest in equal annual installments over the first four years after the vesting commencement date, January 15, 2020. Read SEC document |
| January 15, 2020 Filed Jan 16, 2020 21:34 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantStock Option (right to buy) · Derivative | 82,500 | $0.00 Strike: $6.16 | $0.00 |
DisclosureSEC source: 0001104659-20-004774 · a4.xml · derivative · entry 1 Huebner Dirk · CIK 0001760345 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2030-01-15 F1 · derivative.exercise_date: The options vest in equal quarterly installments over the first four years after the vesting commencement date, January 15, 2020. Read SEC document |
| July 17, 2019 Filed Jul 19, 2019 20:02 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-041099 · a4.xml · derivative · entry 1 Huebner Dirk · CIK 0001760345 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: The restricted stock units vest fully on July 15, 2021. F2 · derivative.expiration_date: The restricted stock units vest fully on July 15, 2021. Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 21:16 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001104659-18-071080 · a4.xml · derivative · entry 1 Huebner Dirk · CIK 0001760345 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-11-30 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on the first anniversary of the grant date and in equal quarterly installments over the next three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.